Walleye Capital’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.06M Buy
27,776
+7,133
+35% +$301K ﹤0.01% 3429
2026
Q2
$971K Sell
20,643
-14,842
-42% -$367K ﹤0.01% 2150
2026
Q1
$671K Buy
+35,485
New +$602K ﹤0.01% 2426
2025
Q4
– Sell
-5,737
Closed -$67.6K – 4925
2025
Q3
$67.6K Buy
+5,737
New +$53.5K ﹤0.01% 3888
2024
Q3
– Sell
-18,487
Closed -$129K – 5667
2024
Q2
$133K Buy
+18,487
New +$162K ﹤0.01% 4562

Other funds holding DFTX

Walleye Capital's DFTX Position: Q3 2026 in Review

Walleye Capital increased its Definium Therapeutics (DFTX) stake by 35% in Q3 2026, buying an estimated $301K and bringing the position to 27,776 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

Walleye Capital first reported a position in DFTX in Q2 2024 and has held it in 5 quarters since. 349 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Walleye Capital held 27,776 shares of Definium Therapeutics worth $1.06M as of Q3 2026.
  • Walleye Capital bought 7,133 Definium Therapeutics shares in Q3 2026, an estimated $301K.
  • Definium Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3429 holding.
  • Walleye Capital first reported a position in Definium Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 349 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.